Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03896633 · ClinicalTrials.gov registry record · Phase 1

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

A Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
Phase 1
Development phase
637
Enrollment target
1
Study location

NCT03896633: Completed Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension, sponsored by Bausch & Lomb Incorporated.

NCT03896633 is a Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 637 participants, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03896633, a Phase 1 study of Glaucoma and Open Angle or Ocular Hypertension, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
Phase 1
Development phase
637 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM

Conditions Studied

Glaucoma Open Angle or Ocular Hypertension

Interventions

  • DRUG brinzolamide 1% ophthalmic suspension
  • DRUG Azopt 1%

Study Locations (1)

New Jersey

  • Various - Bridgewater

Trial Details

FieldValue
Enrollment Target 637 participants
Start Date 2018-02-28
Est. Completion 2018-11-17
Phase Phase 1
Bausch & Lomb Incorporated

174 total trials

What the finished NCT03896633 record still lists

NCT03896633 is an interventional study that assigns participants to a tested intervention. The registered 637 participants enrollment target is mid-sized for trials with a published cap, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (30% lower).

The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which brinzolamide 1% ophthalmic suspension is the first listed.

NCT03896633 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT03896633 about?

NCT03896633 is a clinical study titled "Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt". The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM

What is the current status of trial NCT03896633?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 637 participants. The study started on 2018-02-28. Estimated completion is 2018-11-17.

What conditions does trial NCT03896633 study?

This clinical trial studies the following conditions: Glaucoma, Open Angle or Ocular Hypertension.

What interventions are being tested in trial NCT03896633?

The interventions under investigation include: brinzolamide 1% ophthalmic suspension (DRUG), Azopt 1% (DRUG).

Who is sponsoring clinical trial NCT03896633?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03896633 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03896633's enrollment target sits among peer trials

637 10th of 92 higher than 83 of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03821129 · 636 participants · NA

    GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

  • NCT03478826 · 635 participants

    Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

  • NCT04339699 · 640 participants · NA

    NobleStitch EL STITCH Trial is a PFO Comparative Trial

  • NCT04979338 · 640 participants · Phase 3

    Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03896633, the US trial registry maintained by the National Library of Medicine. NCT03896633 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.